STOPCAP

Maximising patient benefit through enhanced evaluation of therapies and better characterisation of metastatic hormone-sensitive prostate cancer

Improving our understanding of metastatic prostate cancer and the effects of current and new treatments

What was this study about?

We want to find out which treatments for metastatic hormone-sensitive prostate cancer are the most effective, and for which men.  We will do this by combining results and (anonymous) patient data from clinical trials to find out which characteristics of a man and his cancer are most useful for predicting his prognosis and his response to treatments.

We will also look for reliable early measures of whether a treatment is working, which can be used to shorten future trials, so men can access newer treatments sooner than they do now.

Finally, we will also try to ensure that the most effective treatments are used in clinical practice.

The STOPCAP Programme has been ongoing since 2018.

Visit this page to see a summary of the results so far.

For more information, visit:

 

What difference did this study make?

Please click below for more information about STOPCAP results, so far:

 

Type of study

Meta-analyses

Contact details

mrcctu.stopcapm1@ucl.ac.uk

Who funded the study?

STOPCAP is funded by Prostate Cancer UK.

When did it take place?

This programme of research is ongoing.

Where did it take place?

The programme is led by the MRC Clinical Trials Unit at University College London, and brings together the results of trials carried out worldwide.

Who was included?

Trials that randomised men with metastatic hormone-sensitive prostate cancer.